{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:24:54Z","timestamp":1787869494854,"version":"build-2784847793"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A critical barrier to maximizing immune checkpoint blockade (ICB) efficacy is the lack of biomarkers that capture the core regulatory dynamics of the tumor microenvironment. We developed IMIREG, a 14-regulon transcriptional signature derived from inferred transcription factor activity that quantifies immune engagement. Validated across 50 immunotherapy cohorts (52 treatment arms) spanning 16 cancer types, IMIREG robustly predicts clinical benefit (mean AUROC\u2009=\u20090.71), consistently outperforming established response and resistance signatures, including the T cell\u2013inflamed, IFN-\u03b3, CD8 T effector, and antigen presentation signatures. Crucially, its predictive utility is specific to the immunotherapy context rather than general prognosis. Single-cell analysis of 21 datasets revealed selective IMIREG enrichment in checkpoint-restrained exhausted\/memory\/effector T cells and pro-inflammatory M1 macrophages, defining an \u201cimmune-engaged but restrained\u201d state primed for therapeutic reactivation. Our lineage-resolved framework classifies IMIREG-high tumors into T cell\u2013, macrophage\u2013, and dual-driven archetypes, revealing that the dual-driven phenotype is markedly diminished in metastatic compared to primary tumors. In triple-negative breast cancer, longitudinal single-cell analysis of neoadjuvant anti-PD-1\/radiotherapy biopsies establishes IMIREG as a dynamic pharmacodynamic marker that discriminates spatial response trajectories, and predicts pathological complete response in on-treatment biopsies collected prior to radiation initiation. Together, IMIREG provides a mechanism-based biomarker that captures anti-tumor immune regulatory circuitry, improving ICB patient stratification and illuminating immune dynamics in cancer progression.<\/jats:p>","DOI":"10.1038\/s41698-026-01453-7","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T05:42:25Z","timestamp":1778046145000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["IMIREG: a lineage-resolved regulon signature unveiling immune engagement archetypes and predicting immunotherapy response across diverse cancers"],"prefix":"10.1038","volume":"10","author":[{"given":"Bashir","family":"Lawal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renu","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshat","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Bhargava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laizhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huayan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Song","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"1453_CR1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56\u201361 (2015).","journal-title":"Science"},{"key":"1453_CR2","doi-asserted-by":"publisher","first-page":"6012","DOI":"10.1200\/JCO.2025.43.16_suppl.6012","volume":"43","author":"D Adkins","year":"2025","unstructured":"Adkins, D. et al. Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): exploratory efficacy analyses of the phase 3 KEYNOTE-689 study. J. Clin. Oncol. 43, 6012\u20136012 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1453_CR3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ejca.2017.09.018","volume":"86","author":"G Roviello","year":"2017","unstructured":"Roviello, G. et al. Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: a meta-regression of randomised prospective studies. Eur. J. Cancer 86, 257\u2013265 (2017).","journal-title":"Eur. J. Cancer"},{"key":"1453_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2019.104523","volume":"101","author":"RC Pestana","year":"2020","unstructured":"Pestana, R. C. et al. Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent\/metastatic head and neck squamous cell carcinoma. Oral Oncol. 101, 104523 (2020).","journal-title":"Oral Oncol."},{"key":"1453_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0518-z","volume":"7","author":"A Capasso","year":"2019","unstructured":"Capasso, A. et al. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. J. Immunother. Cancer 7, 37 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1453_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-017-0243-4","volume":"5","author":"S Gnjatic","year":"2017","unstructured":"Gnjatic, S. et al. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J. Immunother. Cancer 5, 1\u201318 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"1453_CR7","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","volume":"16","author":"AM Goodman","year":"2017","unstructured":"Goodman, A. M. et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol. Cancer Ther. 16, 2598\u20132608 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"1453_CR8","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124\u2013128 (2015).","journal-title":"Science"},{"key":"1453_CR9","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-\u03b3\u2013related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Investig. 127, 2930\u20132940 (2017).","journal-title":"J. Clin. Investig."},{"key":"1453_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/srep00765","volume":"2","author":"JL Messina","year":"2012","unstructured":"Messina, J. L. et al. 12-chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci. Rep. 2, 765 (2012).","journal-title":"Sci. Rep."},{"key":"1453_CR11","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar3593","volume":"362","author":"R Cristescu","year":"2018","unstructured":"Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade\u2013based immunotherapy. Science 362, eaar3593 (2018).","journal-title":"Science"},{"key":"1453_CR12","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1038\/s41591-018-0157-9","volume":"24","author":"N Auslander","year":"2018","unstructured":"Auslander, N. et al. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat. Med. 24, 1545\u20131549 (2018).","journal-title":"Nat. Med."},{"key":"1453_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69\u201374 (2015).","journal-title":"Science"},{"key":"1453_CR14","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","volume":"32","author":"DJ McGrail","year":"2021","unstructured":"McGrail, D. J. et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann. Oncol. 32, 661\u2013672 (2021).","journal-title":"Ann. Oncol."},{"key":"1453_CR15","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman, W. H., Pag\u00e8s, F., Saut\u00e8s-Fridman, C. & Galon, J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12, 298\u2013306 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"1453_CR16","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado, R. et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann. Oncol. 26, 259\u2013271 (2015).","journal-title":"Ann. Oncol."},{"key":"1453_CR17","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24, 541\u2013550 (2018).","journal-title":"Nat. Med."},{"key":"1453_CR18","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1101\/gr.240663.118","volume":"29","author":"L Garcia-Alonso","year":"2019","unstructured":"Garcia-Alonso, L., Holland, C. H., Ibrahim, M. M., Turei, D. & Saez-Rodriguez, J. Benchmark and integration of resources for the estimation of human transcription factor activities. Genome Res. 29, 1363\u20131375 (2019).","journal-title":"Genome Res."},{"key":"1453_CR19","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/ng.3593","volume":"48","author":"MJ Alvarez","year":"2016","unstructured":"Alvarez, M. J. et al. Functional characterization of somatic mutations in cancer using network-based inference of protein activity. Nat. Genet. 48, 838\u2013847 (2016).","journal-title":"Nat. Genet."},{"key":"1453_CR20","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"1453_CR21","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.ccell.2022.05.005","volume":"40","author":"DM Wolf","year":"2022","unstructured":"Wolf, D. M. et al. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: predictive biomarkers across 10 cancer therapies. Cancer Cell 40, 609\u2013623 (2022).","journal-title":"Cancer Cell"},{"key":"1453_CR22","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s12276-021-00559-1","volume":"53","author":"MG Noh","year":"2021","unstructured":"Noh, M. G. et al. Practical prediction model of the clinical response to programmed death-ligand 1 inhibitors in advanced gastric cancer. Exp. Mol. Med. 53, 223\u2013234 (2021).","journal-title":"Exp. Mol. Med."},{"key":"1453_CR23","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","volume":"35","author":"TN Gide","year":"2019","unstructured":"Gide, T. N. et al. Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/anti-CTLA-4 combined therapy. Cancer Cell 35, 238\u2013255 (2019).","journal-title":"Cancer Cell"},{"key":"1453_CR24","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41587-019-0055-9","volume":"37","author":"J Zhang","year":"2019","unstructured":"Zhang, J. et al. The International Cancer Genome Consortium Data Portal. Nat. Biotechnol. 37, 367\u2013369 (2019).","journal-title":"Nat. Biotechnol."},{"key":"1453_CR25","doi-asserted-by":"publisher","unstructured":"Yamaguchi, H., Hsu, J.-M., Sun, L., Wang, S.-C. & Hung, M.-C. Advances and prospects of biomarkers for immune checkpoint inhibitors. Cell Rep. Med. 5, https:\/\/doi.org\/10.1016\/j.xcrm.2024.101621 (2024).","DOI":"10.1016\/j.xcrm.2024.101621"},{"key":"1453_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02179-5","volume":"23","author":"J Wei","year":"2024","unstructured":"Wei, J., Li, W., Zhang, P., Guo, F. & Liu, M. Current trends in sensitizing immune checkpoint inhibitors for cancer treatment. Mol. Cancer 23, 279 (2024).","journal-title":"Mol. Cancer"},{"key":"1453_CR27","doi-asserted-by":"publisher","unstructured":"Aliazis, K. et al. The tumor microenvironment\u2019s role in the response to immune checkpoint blockade. Nat. Cancer, https:\/\/doi.org\/10.1038\/s43018-025-00986-3 (2025).","DOI":"10.1038\/s43018-025-00986-3"},{"key":"1453_CR28","doi-asserted-by":"crossref","unstructured":"Zhang, H. et al. Intragenic rearrangement burden associates with immune cell infiltration and response to immune checkpoint blockade in cancer. Cancer Immunol. Res. 12, 287\u2013295 (2024).","DOI":"10.1158\/2326-6066.CIR-22-0637"},{"key":"1453_CR29","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1158\/2326-6066.CIR-23-0932","volume":"12","author":"Y Wang","year":"2024","unstructured":"Wang, Y., Hu, M., Finn, O. J. & Wang, X. S. Tumor-associated antigen burden correlates with immune checkpoint blockade benefit in tumors with low levels of T-cell exhaustion. Cancer Immunol. Res. 12, 1589\u20131602 (2024).","journal-title":"Cancer Immunol. Res."},{"key":"1453_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhl\u00e9n","year":"2015","unstructured":"Uhl\u00e9n, M. et al. Tissue-based map of the human proteome. Science 347, 1260419 (2015).","journal-title":"Science"},{"key":"1453_CR31","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.ccell.2024.04.011","volume":"42","author":"MJ van Elsas","year":"2024","unstructured":"van Elsas, M. J. et al. Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy. Cancer Cell 42, 1032\u20131050 (2024).","journal-title":"Cancer Cell"},{"key":"1453_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113678","volume":"144","author":"W Li","year":"2025","unstructured":"Li, W. et al. IRF1 transcriptionally up-regulates CXCL10 which increases CD8+ T cells infiltration in colorectal cancer. Int. Immunopharmacol. 144, 113678 (2025).","journal-title":"Int. Immunopharmacol."},{"key":"1453_CR33","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","volume":"41","author":"S-R Woo","year":"2014","unstructured":"Woo, S.-R. et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41, 830\u2013842 (2014).","journal-title":"Immunity"},{"key":"1453_CR34","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/ni.1990","volume":"12","author":"T Krausgruber","year":"2011","unstructured":"Krausgruber, T. et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat. Immunol. 12, 231\u2013238 (2011).","journal-title":"Nat. Immunol."},{"key":"1453_CR35","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s00262-011-1104-5","volume":"60","author":"CM Wilke","year":"2011","unstructured":"Wilke, C. M. et al. Dual biological effects of the cytokines interleukin-10 and interferon-\u03b3. Cancer Immunol. Immunother. 60, 1529\u20131541 (2011).","journal-title":"Cancer Immunol. Immunother."},{"key":"1453_CR36","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry, E. J. & Kurachi, M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15, 486\u2013499 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"1453_CR37","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1158\/0008-5472.CAN-21-4141","volume":"82","author":"L Jenkins","year":"2022","unstructured":"Jenkins, L. et al. Cancer-associated fibroblasts suppress CD8+ T-cell infiltration and confer resistance to immune-checkpoint blockade. Cancer Res. 82, 2904\u20132917 (2022).","journal-title":"Cancer Res."},{"key":"1453_CR38","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adh8005","volume":"15","author":"BH Herzog","year":"2023","unstructured":"Herzog, B. H. et al. Tumor-associated fibrosis impairs immune surveillance and response to immune checkpoint blockade in non\u2013small cell lung cancer. Sci. Transl. Med. 15, eadh8005 (2023).","journal-title":"Sci. Transl. Med."},{"key":"1453_CR39","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s41586-023-06130-4","volume":"618","author":"A Gavish","year":"2023","unstructured":"Gavish, A. et al. Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours. Nature 618, 598\u2013606 (2023).","journal-title":"Nature"},{"key":"1453_CR40","doi-asserted-by":"crossref","unstructured":"Jaume, G. et al. HEST-1k: a dataset for spatial transcriptomics and histology image analysis. Adv. Neural Inf. Process. Syst. 37, 53798\u201353833 (2024).","DOI":"10.52202\/079017-1704"},{"key":"1453_CR41","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/nar\/30.1.207","volume":"30","author":"R Edgar","year":"2002","unstructured":"Edgar, R., Domrachev, M. & Lash, A. E. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30, 207\u2013210 (2002).","journal-title":"Nucleic Acids Res."},{"key":"1453_CR42","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/ng1007-1181","volume":"39","author":"MD Mailman","year":"2007","unstructured":"Mailman, M. D. et al. The NCBI dbGaP database of genotypes and phenotypes. Nat Genet. 39, 1181\u20131186 (2007).","journal-title":"Nat Genet."},{"key":"1453_CR43","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman, M. J. et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat. Biotechnol. 38, 675\u2013678 (2020).","journal-title":"Nat. Biotechnol."},{"key":"1453_CR44","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.celrep.2018.03.086","volume":"23","author":"J Saltz","year":"2018","unstructured":"Saltz, J. et al. Spatial organization and molecular correlation of tumor-infiltrating lymphocytes using deep learning on pathology images. Cell Rep. 23, 181\u2013193 (2018).","journal-title":"Cell Rep."},{"key":"1453_CR45","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","volume":"39","author":"A Bagaev","year":"2021","unstructured":"Bagaev, A. et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell 39, 845\u2013865 (2021).","journal-title":"Cancer Cell"},{"key":"1453_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9971","volume":"6","author":"D Aran","year":"2015","unstructured":"Aran, D., Sirota, M. & Butte, A. J. Systematic pan-cancer analysis of tumour purity. Nat. Commun. 6, 8971 (2015).","journal-title":"Nat. Commun."},{"key":"1453_CR47","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453\u2013457 (2015).","journal-title":"Nat. Methods"},{"key":"1453_CR48","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1453_CR49","doi-asserted-by":"publisher","first-page":"baz046","DOI":"10.1093\/database\/baz046","volume":"2019","author":"O Franz\u00e9n","year":"2019","unstructured":"Franz\u00e9n, O., Gan, L.-M. & Bj\u00f6rkegren, J. L. M. PanglaoDB: a web server for exploration of mouse and human single-cell RNA sequencing data. Database 2019, baz046 (2019).","journal-title":"Database"},{"key":"1453_CR50","doi-asserted-by":"publisher","unstructured":"Chi, X. et al. Universal concept signature analysis: genome-wide quantification of new biological and pathological functions of genes and pathways. Brief. Bioinform. https:\/\/doi.org\/10.1093\/bib\/bbz093 (2019).","DOI":"10.1093\/bib\/bbz093"},{"key":"1453_CR51","doi-asserted-by":"publisher","first-page":"btad325","DOI":"10.1093\/bioinformatics\/btad325","volume":"39","author":"L Deng","year":"2023","unstructured":"Deng, L. et al. IndepthPathway: an integrated tool for in-depth pathway enrichment analysis based on bulk and single cell sequencing data. Bioinformatics 39, btad325 (2023).","journal-title":"Bioinformatics"},{"key":"1453_CR52","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587 (2021).","journal-title":"Cell"},{"key":"1453_CR53","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe6474","volume":"374","author":"L Zheng","year":"2021","unstructured":"Zheng, L. et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science 374, abe6474 (2021).","journal-title":"Science"},{"key":"1453_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23324-4","volume":"12","author":"M Andreatta","year":"2021","unstructured":"Andreatta, M. et al. Interpretation of T cell states from single-cell transcriptomics data using reference atlases. Nat. Commun. 12, 2965 (2021).","journal-title":"Nat. Commun."},{"key":"1453_CR55","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cell.2021.01.010","volume":"184","author":"S Cheng","year":"2021","unstructured":"Cheng, S. et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell 184, 792\u2013809 (2021).","journal-title":"Cell"},{"key":"1453_CR56","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.it.2022.04.008","volume":"43","author":"R-Y Ma","year":"2022","unstructured":"Ma, R.-Y., Black, A. & Qian, B.-Z. Macrophage diversity in cancer revisited in the era of single-cell omics. Trends Immunol. 43, 546\u2013563 (2022).","journal-title":"Trends Immunol."},{"key":"1453_CR57","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.cell.2018.05.060","volume":"174","author":"E Azizi","year":"2018","unstructured":"Azizi, E. et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell 174, 1293\u20131308 (2018).","journal-title":"Cell"},{"key":"1453_CR58","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/j.cell.2017.10.044","volume":"171","author":"SV Puram","year":"2017","unstructured":"Puram, S. V. et al. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell 171, 1611\u20131624 (2017).","journal-title":"Cell"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01453-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01453-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01453-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T20:01:39Z","timestamp":1780516899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01453-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1453"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01453-7","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"22 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"X.-S.W. is the founder of CA-Genome Rx Inc. CA-Genome Rx Inc. was not involved in the design, execution, analysis, or interpretation of this study, and no products, patents, or intellectual property related to CA-Genome Rx Inc. are discussed or evaluated in this work. The remaining authors (B.L., A.G., R.S., Z.L., H.R., R.B., and Y.W.) declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"201"}}